Key Takeaways
- CapVest Partners' proposed €10 billion acquisition of German drugmaker Stada Arzneimittel has reportedly collapsed, with discussions faltering over differences in valuation and bid structure.
- Stada's private equity owners, Bain Capital and Cinven, are now actively resuming preparations for an Initial Public Offering (IPO), which could take place as early as October 2025.
- The potential sale to CapVest would have marked one of Europe's largest private equity transactions of 2025, but the renewed focus on an IPO signals a significant shift in exit strategy.
- Stada, a leading producer of generic and over-the-counter medicines, reported €2.12 billion in revenue for the first half of 2025 and expects 2025 adjusted EBITDA between €930 million and €990 million.
Stalled Acquisition Talks Lead to IPO Revival
London-based private equity firm CapVest Partners was in advanced discussions to acquire a majority stake in German pharmaceutical company Stada Arzneimittel, a deal that could have valued the business at approximately €10 billion including debt. However, these negotiations have reportedly stalled or broken down, primarily due to disagreements over valuation and the structure of the proposed bid. This development potentially ends a long-running saga to sell the German drugmaker.
Following the breakdown of talks with CapVest, Stada's current owners, private equity firms Bain Capital and Cinven, are now pivoting back to an Initial Public Offering (IPO). Preparations for a listing are reportedly resuming, with an IPO potentially occurring as early as October 2025. This marks a significant shift, as an IPO has long been considered an alternative exit strategy for Bain Capital and Cinven.
Stada's Ownership History and Business Profile
Bain Capital and Cinven acquired Stada in 2017 for €5.3 billion, taking the company private from the Frankfurt Stock Exchange. Since then, Stada has expanded through several acquisitions, solidifying its position as a major European producer of generic drugs, over-the-counter (OTC) healthcare products, and specialty medicines for rare and chronic conditions. Its well-known brands include Grippostad for cold and flu treatment and Hirudoid cream for bruises.
The company had previously explored an IPO in March 2025 but paused those plans due to market volatility stemming from geopolitical events. The renewed push for a public listing underscores the owners' determination to find an exit for their investment.
Financial Performance and Market Context
Stada reaffirmed its 2025 financial targets in June, projecting adjusted EBITDA between €930 million and €990 million on revenues of €4.25 billion to €4.4 billion. In the first half of 2025, the company reported strong performance with 6% year-over-year revenue growth, reaching €2.12 billion. This growth was partly attributed to the July 2024 launch of Uzpruvo, a biosimilar to Johnson & Johnson's Stelara, developed in partnership with Alvotech.
The generic and OTC drug market continues to attract significant interest from private equity firms due to its stable cash flows. While the CapVest deal would have been one of the largest European pharma transactions of the year, the focus now shifts to how Stada's potential IPO will be received by the market and what valuation it might achieve as a publicly traded entity.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.